NCT05567185 2026-03-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT04572295 2026-03-11
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Phase 1 Active not recruiting
NCT04238715 2026-03-02
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Inc.
Phase 2 Completed